Materialise, a leader in 3D printing software and services, recently acquired FEops, a Belgian company specializing in AI-driven simulation technology for structural heart interventions. This acquisition will allow Materialise to enhance its cardiovascular solutions by integrating predictive simulation capabilities, ultimately improving personalized treatment for patients with heart diseases.
FEops’ technology combines predictive simulation and artificial intelligence to help clinicians accurately predict how transcatheter structural heart devices will interact with a patient’s unique anatomy. By integrating FEops’ technology with Materialise’s Mimics Planner for Structural Heart Interventions, clinicians will have a comprehensive solution for anatomy-based 3D planning and AI-based simulation.
This advancement is set to revolutionize patient care for structural heart diseases by offering a more interactive and personalized solution for preparing heart procedures. The integration of advanced visualization and simulation technologies will not only enhance the accuracy and efficiency of structural heart interventions but also improve clinical outcomes and patient safety.
Structural heart diseases, such as heart valve diseases, are a significant medical and economic burden globally. By 2030, the annual costs associated with adverse outcomes from heart valve diseases are projected to reach 70 billion USD. Materialise’s focus on mass personalization in healthcare, through the creation of image-based virtual 3D models for pre-procedural planning, aims to enhance the precision and success of complex procedures, ultimately making personalized healthcare more efficient and accessible to a broader range of patients.
Source
Photo credit www.voxelmatters.com